Gao, Pan
Lyu, Qing
Ghanam, Amr R.
Lazzarotto, Cicera R.
Newby, Gregory A.
Zhang, Wei
Choi, Mihyun
Slivano, Orazio J.
Holden, Kevin
Walker, John A. II
Kadina, Anastasia P.
Munroe, Rob J.
Abratte, Christian M.
Schimenti, John C.
Liu, David R.
Tsai, Shengdar Q.
Long, Xiaochun
Miano, Joseph M. http://orcid.org/0000-0001-7522-3207
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (HL138987, HL136224, HL147476, HL122686, HL139794)
National Institute on Aging (U142756, 15055101)
National Institutes of Health (UG3TR002636)
National Human Genome Research Institute (009490)
National Institute of General Medical Sciences (118062)
Helen Hay Whitney Foundation
American Heart Association (18CDA34110319)
Article History
Received: 21 November 2020
Accepted: 24 February 2021
First Online: 16 March 2021
Declarations
:
: All mouse work was approved by local Institutional Animal Care and Use Committees at the Medical College of Georgia (protocol #2019-0999 and #2019-1000) and Cornell University (protocol #2000-0122).
: NA
: DRL is a consultant and co-founder of Editas Medicine, Pairwise Plants, Beam Therapeutics, and Prime Medicine, companies that use genome-editing technologies. KH, JAW, and APK are employees of Synthego Corporation. CRL and SQT have filed a patent application on CHANGE-seq. SQT is a member of the scientific advisory board of Kromatid.